Preclinical studies have shown that, in addition to showing anti-multiple-myeloma activity as single agents, new agents such as bortezomib also enhance the efficacy of chemotherapy and steroids. A randomised trial has now established that bortezomib prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.
Leave a Reply